Prolixin Does Not Increase Ammonia Levels
Based on the FDA drug label and available evidence, fluphenazine (Prolixin) is not known to increase blood ammonia levels. There is no documented association between this antipsychotic medication and hyperammonemia.
Evidence Review
FDA Drug Label Findings
The official Prolixin prescribing information 1 provides comprehensive adverse effect profiles and does not list hyperammonemia or elevated ammonia levels among the known side effects. The label extensively details:
- Metabolic/endocrine effects: Weight change, peripheral edema, abnormal lactation, gynecomastia, menstrual irregularities
- Hepatic effects: Cholestatic jaundice, altered liver function tests
- Hematologic effects: Leukopenia, agranulocytosis, thrombocytopenia
- Cardiovascular effects: Hypotension, blood pressure fluctuations
- Neurological effects: Extrapyramidal symptoms, tardive dyskinesia, seizures
Notably absent is any mention of ammonia elevation or hyperammonemia.
Guideline Context on Drug-Induced Hyperammonemia
The 2020 consensus guidelines on hyperammonemia 2 specifically identify drugs that can cause secondary hyperammonemia through urea cycle inhibition. The only medication explicitly mentioned is valproic acid, which causes competitive inhibition of N-acetylglutamate synthase (NAGS). Fluphenazine is not mentioned in this context.
Clinical Research Evidence
Multiple pharmacokinetic and clinical studies of fluphenazine 3, 4, 5, 6, 7 examined plasma levels, side effects, and clinical outcomes. None reported ammonia elevation as an adverse effect or monitoring parameter.
Clinical Implications
When to Consider Alternative Causes
If a patient on Prolixin presents with elevated ammonia levels, investigate other etiologies:
- Hepatic dysfunction: Cirrhosis, acute liver failure, hepatic encephalopathy 8
- Medications: Valproic acid (the primary drug culprit) 2
- Metabolic disorders: Urea cycle disorders, organic acidemias 2
- Acute illness: Kidney injury, severe infection, gastrointestinal bleeding
Monitoring Recommendations
The FDA label 1 recommends monitoring:
- Renal function (BUN) during long-term therapy
- Hepatic function periodically
- Complete blood counts for hematologic effects
Ammonia monitoring is not indicated for patients on fluphenazine unless other risk factors for hyperammonemia are present.
Important Caveat
While fluphenazine can cause hepatic dysfunction (cholestatic jaundice) 1, this is distinct from hyperammonemia. Liver damage severe enough to impair the urea cycle and cause secondary hyperammonemia would be accompanied by other signs of hepatic failure and is not a characteristic adverse effect of this medication.